Arrowhead Pharmaceuticals (ARWR) said Tuesday it had filed a request for regulatory clearance to initiate a phase 1/2a clinical trial of its experimental therapy, ARO-ALK7, to treat obesity.
The company said the application was submitted to the New Zealand Medicines and Medical Devices Safety Authority for review.
It added pending approval, the company plans to evaluate the safety and tolerability of ARO-ALK7 in up to 90 adult volunteers with obesity.
The trial will consist of two parts, where the first part will assess single and multiple doses of ARO-ALK7 monotherapy, while the second part will evaluate ARO-ALK7 in combination with tirzepatide, an approved treatment for type 2 diabetes and weight management.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。